YU33203A - Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti - Google Patents

Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti

Info

Publication number
YU33203A
YU33203A YU33203A YUP33203A YU33203A YU 33203 A YU33203 A YU 33203A YU 33203 A YU33203 A YU 33203A YU P33203 A YUP33203 A YU P33203A YU 33203 A YU33203 A YU 33203A
Authority
YU
Yugoslavia
Prior art keywords
radiopharmaceuticals
disease
diagnosing alzheimer
alzheimer
diagnosing
Prior art date
Application number
YU33203A
Other languages
English (en)
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
Jorg Steinbach
Peter Mading
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E. Hesselgesser
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of YU33203A publication Critical patent/YU33203A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ovaj pronalazak je usmeren na upotrebu radioaktivnih farmaceutskih sredstava u dijagnostikovanju Alchajmerove bolesti. Tačnije radioaktivna farmaceutska sredstva pronalaska sposobna su da prodju kroz krv-mozak barijeru i da se vezuju na CCR1 receptor prisutan u tkivu mozga pacijenata sa Alchajmerovom bolešću.[This invention is directed to the use of radiopharmaceuticals of formula (I) in diagnosing Alzheimer's disease. In particular the radiopharmaceuticals of the invention are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.
YU33203A 2000-11-06 2001-11-01 Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti YU33203A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06

Publications (1)

Publication Number Publication Date
YU33203A true YU33203A (sh) 2006-05-25

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
YU33203A YU33203A (sh) 2000-11-06 2001-11-01 Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti

Country Status (29)

Country Link
US (2) US6676926B2 (sh)
EP (1) EP1332138B1 (sh)
JP (1) JP4234425B2 (sh)
KR (1) KR20030045167A (sh)
CN (1) CN1473158A (sh)
AR (1) AR035366A1 (sh)
AT (1) ATE314354T1 (sh)
AU (2) AU1403402A (sh)
BG (1) BG107762A (sh)
BR (1) BR0115150A (sh)
CA (1) CA2424598A1 (sh)
DE (1) DE60116365T2 (sh)
EA (1) EA006199B1 (sh)
EE (1) EE200300216A (sh)
HR (1) HRP20030459A2 (sh)
HU (1) HUP0301710A3 (sh)
IL (1) IL155191A0 (sh)
JO (1) JO2207B1 (sh)
MX (1) MXPA03003759A (sh)
NO (1) NO20032007L (sh)
NZ (1) NZ525303A (sh)
PE (1) PE20020531A1 (sh)
PL (1) PL361631A1 (sh)
SK (1) SK287495B6 (sh)
TW (1) TWI238820B (sh)
UY (1) UY27003A1 (sh)
WO (1) WO2002036581A1 (sh)
YU (1) YU33203A (sh)
ZA (1) ZA200304409B (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CN1575283A (zh) 2001-10-22 2005-02-02 辉瑞产品公司 具有ccr1受体拮抗剂活性的哌嗪衍生物
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2305769T3 (es) * 2003-05-07 2008-11-01 Bayer Schering Pharma Aktiengesellschaft Dispositivo y procedimiento para la fluoracion nucleofila.
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
JP5070038B2 (ja) * 2004-02-24 2012-11-07 ザ ジェネラル ホスピタル コーポレーション 触媒性放射性フッ素化
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
CA2663121C (en) 2006-09-08 2016-01-19 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
JP5864077B2 (ja) 2006-09-08 2016-02-17 ロード アイランド ホスピタル アルコール誘発性肝疾患の治療、予防および回復
JP5562036B2 (ja) * 2006-12-21 2014-07-30 ハマースミス・イメイネット・リミテッド 放射性標識方法
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
CA2703563A1 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
CA2978149C (en) 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
ES2973048T3 (es) 2013-12-27 2024-06-18 Univ Nat Corp Tokyo Medical & Dental Método para el diagnóstico de la enfermedad de Alzheimer y la degeneración lobar frontotemporal, agente de diagnóstico, agente terapéutico y método de cribado ("screening") para dichos agentes
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016239A1 (en) 1991-03-13 1992-10-01 The Regents Of The University Of Minnesota Radiopharmaceutical agents for the detection of alzheimer's disease
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
WO1997040010A1 (en) * 1996-04-24 1997-10-30 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
CA2361366A1 (en) 1999-03-26 2000-10-05 Nicholas Kindon Novel compounds
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
ZA200304409B (en) 2004-09-06
AR035366A1 (es) 2004-05-12
US20020131932A1 (en) 2002-09-19
NO20032007D0 (no) 2003-05-05
AU2002214034B2 (en) 2006-01-05
US6676926B2 (en) 2004-01-13
EP1332138A1 (en) 2003-08-06
EP1332138B1 (en) 2005-12-28
DE60116365T2 (de) 2006-08-24
TWI238820B (en) 2005-09-01
BG107762A (en) 2004-03-31
MXPA03003759A (es) 2003-07-28
HUP0301710A3 (en) 2007-03-28
SK5472003A3 (en) 2003-10-07
IL155191A0 (en) 2003-11-23
HUP0301710A2 (hu) 2003-11-28
UY27003A1 (es) 2002-07-31
JO2207B1 (en) 2004-10-07
EA006199B1 (ru) 2005-10-27
US6872381B1 (en) 2005-03-29
BR0115150A (pt) 2003-12-30
AU1403402A (en) 2002-05-15
DE60116365D1 (de) 2006-02-02
JP2004513123A (ja) 2004-04-30
EE200300216A (et) 2003-08-15
CN1473158A (zh) 2004-02-04
CA2424598A1 (en) 2002-05-10
PL361631A1 (en) 2004-10-04
SK287495B6 (sk) 2010-12-07
KR20030045167A (ko) 2003-06-09
EA200300507A1 (ru) 2003-12-25
NZ525303A (en) 2004-10-29
NO20032007L (no) 2003-07-02
PE20020531A1 (es) 2002-06-15
HRP20030459A2 (en) 2005-04-30
JP4234425B2 (ja) 2009-03-04
ATE314354T1 (de) 2006-01-15
WO2002036581A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GB0025173D0 (en) Therapeutic agents
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
LTPA2015001I1 (lt) Tioflavino dariniai ir jų panaudojimas Alzhaimerio ligos diagnostikai ir terapijai
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
GB0108592D0 (en) Therapeutic agents
GEP20053655B (en) 5-HT Receptor Ligands and Uses Thereof
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
ATE314067T1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
TNSN04165A1 (en) Substituted hydroxyethylamines
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
GB0011430D0 (en) Acombination of therapeutic agents for treating Alzheimer's Disease
WO2001080906A3 (en) Radiometal complexes of 2-pyrrolylthiones for imaging a therapy
PT2266558T (pt) Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
TH65073A (th) รังสีเภสัชกรรมสำหรับการวินิจฉัยโรคแอลไซเมอร์
ES2190373A1 (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.